Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tear Evaporation Rate with Systane Complete in Dry Eye vs Non-Dry Eye
NCT04091581Phase 4Completed
- Sponsor
- University of Waterloo
- Start
- Nov 2019
- Primary completion
- Feb 2020
- Modality
- Nanoparticles, Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
Phase 4, open-label trial of propylene glycol-hydroxypropyl guar nanoemulsion in dry eye syndrome (DED) (2 arms), sponsored by University of Waterloo. Primary endpoint: Tear Evaporation Rate. Started Nov 2019; status: completed.
02
Drugs
propylene glycol-hydroxypropyl guar nanoemulsion
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on NCT04091581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04091581.